Bhatt, D. L., Briggs, A., Reed, S. D., Annemans, L., Szarek, M., Bittner, V. A., … Steg, G. (2018). Cost-Effectiveness of Alirocumab Based on Evidence From a Large Multinational Outcome Trial: The ODYSSEY OUTCOMES Economics Study. In CIRCULATION (Vol. 138, pp. E753–E754). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.

Bhatt, Deepak L., Andrew Briggs, Shelby D. Reed, Lieven Annemans, Michael Szarek, Vera A. Bittner, Rafael Diaz, et al. “Cost-Effectiveness of Alirocumab Based on Evidence From a Large Multinational Outcome Trial: The ODYSSEY OUTCOMES Economics Study.” In CIRCULATION, 138:E753–54. LIPPINCOTT WILLIAMS & WILKINS, 2018.

Bhatt DL, Briggs A, Reed SD, Annemans L, Szarek M, Bittner VA, et al. Cost-Effectiveness of Alirocumab Based on Evidence From a Large Multinational Outcome Trial: The ODYSSEY OUTCOMES Economics Study. In: CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2018. p. E753–4.

Bhatt, Deepak L., et al. “Cost-Effectiveness of Alirocumab Based on Evidence From a Large Multinational Outcome Trial: The ODYSSEY OUTCOMES Economics Study.” CIRCULATION, vol. 138, no. 25, LIPPINCOTT WILLIAMS & WILKINS, 2018, pp. E753–54.

Bhatt DL, Briggs A, Reed SD, Annemans L, Szarek M, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Sanchez R, Higuchi K, White HD, Zeiher AM, Schwartz GG, Steg G. Cost-Effectiveness of Alirocumab Based on Evidence From a Large Multinational Outcome Trial: The ODYSSEY OUTCOMES Economics Study. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2018. p. E753–E754.